Screening for Lipid Disorders in Adults: Selective Update of 2001 US Preventive Services Task Force Review

Authors' conclusions There is no new evidence relevant to screening younger adults or to appropriate screening intervals. Evidence is conflicting regarding the additional contribution of a serum triglyceride level to the identification of individuals at shortterm risk for coronary heart disease events. The balance of benefits and harms is clearly in favor of statin therapy among individuals enrolled in some, but not all, randomized trials of primary prevention. The long-term harms of statin therapy are unknown.